Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- PhRMA Reserves Opinion on INES Proposal, but Says No to Any Cherry-Picking
October 29, 2021
- Kazuhiko Ezawa to Become Chuikyo JMA Rep after Matsumoto
October 28, 2021
- JGA Sets Out 5-Pronged Measures to Restore Trust in Generics
October 27, 2021
- Kenporen’s Masato Matsumoto to Take Over from Kono as Chuikyo Payer Rep
October 27, 2021
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
- Plaintiffs, Lawyers Renew Opposition to Restart of HPV Vaccine Recommendation
October 13, 2021
- JGA Vows Strict Response to Choseido’s Biz Suspension Order
October 12, 2021
- IFPW Chair Vows to Boost Reliability of Healthcare Supply Chain as Tokyo Confab Ends
October 8, 2021
- INES’ Patient-Centered Policy Initiative Going Full Throttle, Proposal Eyed before 2022 Honebuto Paper
October 7, 2021
- JMA Exec Chides Pharma for Requesting Price Measure to Ensure Stable Supplies, Says Compliance System Should Come First
October 7, 2021
- Biocommunity for Greater Tokyo Area Boots Up, Aims to Form Bioinnovation Hub
October 7, 2021
- Amy Jackson to Leave PhRMA Japan, Kawabata to Take Up Interim Role
October 6, 2021
- 1,749 Generic Products Now under Supply Restrictions: JGA
October 5, 2021
- Think Twice before Issuing Long-Term Prescriptions for Supply-Curbed Generics: JMA
October 5, 2021
- MEJ Study Group Calls for Electronic Medical Chart Reform to Expedite Clinical Trials, New Drug Development
October 4, 2021
- FPMAJ to Define Shipment Situation in Preparation for Supply Information Centralization
October 1, 2021
- FPMAJ Chief Praises Political Acumen of New LDP Leader Kishida, Seeks Support for Industry
September 30, 2021
- Generic Use Rate Slips to 79.8% in April-June: JGA
September 30, 2021
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…